Sutro Biopharma (STRO) Competitors $0.89 +0.05 (+6.17%) As of 01:41 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock STRO vs. ATYR, ATAI, ACB, AQST, CMPX, DBVT, CRVS, IMMP, RNAC, and AURAShould you be buying Sutro Biopharma stock or one of its competitors? The main competitors of Sutro Biopharma include Atyr PHARMA (ATYR), Atai Life Sciences (ATAI), Aurora Cannabis (ACB), Aquestive Therapeutics (AQST), Compass Therapeutics (CMPX), DBV Technologies (DBVT), Corvus Pharmaceuticals (CRVS), Immutep (IMMP), Cartesian Therapeutics (RNAC), and Aura Biosciences (AURA). These companies are all part of the "pharmaceutical products" industry. Sutro Biopharma vs. Atyr PHARMA Atai Life Sciences Aurora Cannabis Aquestive Therapeutics Compass Therapeutics DBV Technologies Corvus Pharmaceuticals Immutep Cartesian Therapeutics Aura Biosciences Atyr PHARMA (NASDAQ:ATYR) and Sutro Biopharma (NASDAQ:STRO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, community ranking, media sentiment, valuation and institutional ownership. Do institutionals & insiders have more ownership in ATYR or STRO? 61.7% of Atyr PHARMA shares are held by institutional investors. Comparatively, 97.0% of Sutro Biopharma shares are held by institutional investors. 3.7% of Atyr PHARMA shares are held by company insiders. Comparatively, 3.6% of Sutro Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the MarketBeat Community believe in ATYR or STRO? Sutro Biopharma received 118 more outperform votes than Atyr PHARMA when rated by MarketBeat users. However, 100.00% of users gave Atyr PHARMA an outperform vote while only 63.46% of users gave Sutro Biopharma an outperform vote. CompanyUnderperformOutperformAtyr PHARMAOutperform Votes14100.00% Underperform VotesNo VotesSutro BiopharmaOutperform Votes13263.46% Underperform Votes7636.54% Which has more risk & volatility, ATYR or STRO? Atyr PHARMA has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500. Comparatively, Sutro Biopharma has a beta of 1.77, suggesting that its stock price is 77% more volatile than the S&P 500. Does the media prefer ATYR or STRO? In the previous week, Atyr PHARMA had 3 more articles in the media than Sutro Biopharma. MarketBeat recorded 9 mentions for Atyr PHARMA and 6 mentions for Sutro Biopharma. Atyr PHARMA's average media sentiment score of 0.81 beat Sutro Biopharma's score of 0.57 indicating that Atyr PHARMA is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atyr PHARMA 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sutro Biopharma 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer ATYR or STRO? Atyr PHARMA presently has a consensus target price of $18.60, suggesting a potential upside of 388.83%. Sutro Biopharma has a consensus target price of $6.11, suggesting a potential upside of 583.16%. Given Sutro Biopharma's higher probable upside, analysts clearly believe Sutro Biopharma is more favorable than Atyr PHARMA.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atyr PHARMA 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14Sutro Biopharma 1 Sell rating(s) 5 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.13 Is ATYR or STRO more profitable? Atyr PHARMA has a net margin of 0.00% compared to Sutro Biopharma's net margin of -77.01%. Atyr PHARMA's return on equity of -79.44% beat Sutro Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Atyr PHARMAN/A -79.44% -59.16% Sutro Biopharma -77.01%-101.89%-28.69% Which has stronger earnings and valuation, ATYR or STRO? Atyr PHARMA has higher earnings, but lower revenue than Sutro Biopharma. Atyr PHARMA is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAtyr PHARMA$235K1,441.11-$50.39M-$0.81-4.70Sutro Biopharma$66.43M1.14-$106.79M-$2.98-0.30 SummaryAtyr PHARMA beats Sutro Biopharma on 12 of the 19 factors compared between the two stocks. Get Sutro Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for STRO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart STRO vs. The Competition Export to ExcelMetricSutro BiopharmaBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$75.59M$2.91B$5.32B$8.44BDividend YieldN/A1.68%5.21%4.11%P/E Ratio-0.5631.0326.8119.78Price / Sales1.14399.44387.95118.50Price / CashN/A168.6838.2534.62Price / Book0.373.226.774.52Net Income-$106.79M-$72.35M$3.23B$248.32M7 Day Performance1.88%4.45%1.73%0.58%1 Month Performance23.48%4.98%10.92%13.09%1 Year Performance-78.99%-27.10%17.16%7.74% Sutro Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)STROSutro Biopharma4.395 of 5 stars$0.89+6.2%$6.11+587.0%-81.5%$75.17M$66.43M-0.55240News CoverageAnalyst ForecastATYRAtyr PHARMA2.8159 of 5 stars$3.24-1.2%$18.60+474.1%N/A$288.37M$235,000.00-3.4553Positive NewsAnalyst ForecastATAIAtai Life Sciences2.3422 of 5 stars$1.44+3.6%$10.50+629.2%+13.7%$287.71M$308,000.00-1.7880News CoverageAnalyst ForecastAnalyst RevisionACBAurora Cannabis0.6327 of 5 stars$5.06+4.3%N/A-26.8%$284.44M$320.81M101.221,340AQSTAquestive Therapeutics1.3156 of 5 stars$2.85+2.2%$10.67+274.3%-28.6%$283.07M$57.56M-6.33160Analyst RevisionCMPXCompass Therapeutics3.6781 of 5 stars$2.01+10.4%$13.13+553.0%+28.8%$277.95M$850,000.00-5.4320DBVTDBV Technologies2.7865 of 5 stars$10.13+3.1%$15.50+53.0%+48.6%$277.46M$15.73M-2.2580Gap DownCRVSCorvus Pharmaceuticals2.3996 of 5 stars$4.05-8.6%$16.33+303.3%+66.5%$276.08MN/A-4.3530Analyst ForecastHigh Trading VolumeIMMPImmutep1.4139 of 5 stars$1.87+1.1%$8.50+354.5%-39.9%$273.09M$5.14M0.002,021Analyst UpgradeRNACCartesian Therapeutics1.55 of 5 stars$10.44+5.5%$42.50+307.1%-62.3%$270.78M$38.91M-0.2064News CoverageAnalyst RevisionAURAAura Biosciences2.6158 of 5 stars$5.35+2.3%$22.75+325.2%-14.2%$268.70MN/A-3.0950Earnings ReportInsider Trade Related Companies and Tools Related Companies Atyr PHARMA Alternatives Atai Life Sciences Alternatives Aurora Cannabis Alternatives Aquestive Therapeutics Alternatives Compass Therapeutics Alternatives DBV Technologies Alternatives Corvus Pharmaceuticals Alternatives Immutep Alternatives Cartesian Therapeutics Alternatives Aura Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:STRO) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredAI Bloodbath Coming on June 1st?If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sutro Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sutro Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy STRO Stock Free STRO Stock Alerts